Last reviewed · How we verify
NCT03527940
Prognostic Markers of Patients With STEMI
trial in STEMI - ST Elevation Myocardial Infarction in 932 participants. Completed in 1 January 2020.
1 July 2019
Quick facts
| Lead sponsor | Chongqing Medical University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 932 |
| Start date | 17 September 2015 |
| Primary completion | 1 July 2019 |
| Estimated completion | 1 January 2020 |
| Sites | 1 location across China |
Conditions studied
- STEMI - ST Elevation Myocardial Infarction — all drugs for STEMI - ST Elevation Myocardial Infarction →
Sponsor
Chongqing Medical University
Who can join
18 and older, any sex, with STEMI - ST Elevation Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To analyze the relationship between the clinical data and the outcomes of STEMI patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Neutrophils to high-density lipoprotein cholesterol ratio as a new prognostic marker in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a retrospective study.
Chen Y, Jiang D, Tao H, Ge P, et al · · 2022 · cited 18× · PMID 36199038 · DOI 10.1186/s12872-022-02870-9
Verify or expand the search:
- PubMed search for NCT03527940
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for STEMI - ST Elevation Myocardial Infarction
Currently open trials in the same condition.
- NCT07160491 — Early Thrombolysis Guided by AI-Assisted App in Patients With STEMI · NA · recruiting
- NCT06013020 — Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus · Phase 4 · recruiting
- NCT06384846 — AI Algorithms in Prediction of ACS Based on Leukocyte Properties · recruiting
- NCT04436978 — What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI? · Phase 4 · recruiting
- NCT05800951 — Can Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock · active not recruiting
Other Chongqing Medical University trials
Trials by the same sponsor.
- NCT07298889 — High PEEP in Noninvasive Ventilation Patients With Pneumonia or ARDS · NA · recruiting
- NCT07503509 — Physiological Study of High PEEP in Noninvasive Ventilation · NA · recruiting
- NCT06118671 — The Evaluation of Artificial Intelligence in Lifestyle Management of Diabetic Patients in Community · NA · unknown
- NCT06272032 — Prospective Multicenter Observational Study and Promotion of the Application of Focused Ultrasound in Allergic Rhinitis · EARLY_PHASE1 · unknown
- NCT05974566 — Efficacy and Safety of Finerenone in Heart Failure With Reduced Ejection Fraction · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03527940 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chongqing Medical University
- Last refreshed: 4 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03527940.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing